Free Trial

Galapagos (GLPG) Competitors

Galapagos logo
$31.14 +0.48 (+1.57%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$31.14 0.00 (0.00%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLPG vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Galapagos vs. Its Competitors

Galapagos (NASDAQ:GLPG) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Galapagos' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score.

Company Overall Sentiment
Galapagos Neutral
180 Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
GalapagosN/A N/A N/A
180 Life Sciences N/A N/A N/A

Galapagos presently has a consensus price target of $25.33, suggesting a potential downside of 18.65%. Given Galapagos' stronger consensus rating and higher probable upside, equities research analysts clearly believe Galapagos is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galapagos
4 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

32.5% of Galapagos shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Galapagos has higher revenue and earnings than 180 Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$298.31MN/A$80.16MN/AN/A
180 Life SciencesN/AN/AN/AN/AN/A

Summary

Galapagos beats 180 Life Sciences on 5 of the 5 factors compared between the two stocks.

Get Galapagos News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLPG vs. The Competition

MetricGalapagosMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.93B$5.53B$9.42B
Dividend YieldN/A2.48%3.76%4.04%
P/E RatioN/A19.8828.2619.78
Price / SalesN/A302.14416.1888.87
Price / Cash42.8941.8435.8558.18
Price / Book0.657.678.115.65
Net Income$80.16M-$55.28M$3.25B$257.97M
7 Day Performance2.77%4.87%1.63%3.74%
1 Month Performance13.57%13.14%7.62%11.95%
1 Year Performance19.04%3.51%32.74%19.22%

Galapagos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLPG
Galapagos
0.3817 of 5 stars
$31.14
+1.6%
$25.33
-18.6%
+19.0%$0.00$298.31M0.001,310Upcoming Earnings
ATNFW
180 Life Sciences
N/A$0.01
+2.5%
N/A-16.4%$0.00N/A0.007Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
flat
N/AN/A$0.00N/A0.002Gap Up
AIMDW
Ainos
N/A$0.12
-0.2%
N/A+311.0%$0.00$106.21K0.0040Gap Up
ALVOW
Alvotech
N/A$1.90
+9.8%
N/A-33.7%$0.00$585.60M0.004Gap Up
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.02
flat
N/AN/A$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.09
-14.2%
N/AN/A$0.00$38.00M0.0070Gap Down
BTMDW
biote
N/A$0.01
+20.1%
N/A-97.3%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.06
-14.8%
N/A-71.5%$0.00N/A0.008Gap Down

Related Companies and Tools


This page (NASDAQ:GLPG) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners